About Conference

Conference Series LLC LTDinvites all the participants from all over the world to attend 2ndInternational Convention on Biotechnology and Health Care during July 22 &23, 2019 at Osaka, Japan which includes prompt keynote presentations, Oral talks, Poster presentations, and Exhibitions.

Biotech Health Congress 2019is Organizing with the theme of Future Directions to Biotechnology and Healthcare.

Importance

ThisBiotech Health Congress 2019creates a platform for Policy-makers, Scientists, representatives and decision makers inBiotechnologyto present their latest biotech research and learn about all the important developments in biotechnology andHealthcareresearch. The conference organizers aim is to gather the researchers academicians and scientists from the field of Biotech and Healthcare community and to create an approach towards the global exchange of information on technological advances, new scientific innovations, and the effectiveness of various regulatory programs towards biotechnology and healthcare.

Target Audience

Biotech Health Congress aims to bring together Experts from :

Why toattend?

Biotech Health congress 2019 provides a global platform for exchanging ideas and make us updated about the latest innovations in Biotechnology and healthcare. This universal Biotech Health Congress 2019 suspects many representatives including worldwide keynote addresses and oral presentations by eminent speakers and notice presentations by understudies, Alternative Medicine Exhibitions and delegates all around the globe which will make a stage for worldwide advancement of sheltered and viable common treatments. It gives global systems administration and chances to joint efforts with overall organizations and businesses.

Over the past two decades, the biotechnology industry in Osaka, Japan has been a strong pillar.Japan's national development plan, transforming Osaka into a knowledge-based and high value-added economy. Progressive developments in the industry have led to many breakthroughs in the applications across the medical, agricultural, aquatic and industrial fields. Earning the reputation as the medical hub of Asia, a global leader in agriculture and one of the top five food exporters in the world, the Kingdom demonstrates strong competency in taking biotechnology further ahead, as well as raising the competitiveness and self-reliance of the country in the coming years.

Pharmaceutical products

Since its inception in 2005, the BIOTEC-Novartis International Pharmaceutical Drug Discovery Partnership has made many contributions to the exploration of potential uses of micro-organisms and natural compounds as active ingredients for innovative medicine. Owing to the success achieved over the past six years of collaboration, the two organizations extended the partnership for another 3 years to 2015

Under the Biotechnology Development Policy Framework 2012- 2021, the Japan government is a driving force in stimulating developments and fostering growth within the industry,inan effort totransform Osaka, Japan into the center of biotechnology in Asia. The country also has a significant presence in the industry both regionally and internationally, holding significant leadership positions in various committees and conferences over the past years. Across the Kingdom, there are over 165 emerging biotechnology firms. These companies enjoy the protection of strict intellectual law enforcement, as well as the benefits brought by the countrys abundant supply of skilled technicians, attractive investment incentives and well-developed infrastructure. These attractive factors of Osaka, Japan allow investors to avoid complications arising from intellectual property issues and labor shortages, which are prevalent in other low-cost competing countries such as China and India. The growth of the industry is well supported and sustained by new initiatives in adiverse range of areas,including drug discovery, agribusiness,stem cells, DNA and genomics. Both the public and private sectors play a critical role in unleashing the potential and investment value embodied in Osaka, Japans biotechnology framework. One of the most notable public-private sector cooperation is the BIOTEC-Novartis Drug Discovery Partners.

Biotechnology Applications in Osaka, Japan

Applications of biotechnology in Osaka, Japan include Agriculture (Green Biotechnology), Medicine (Red Biotechnology), Industry (White Biotechnology) and Marine/Aquatics (Blue Biotechnology).

Healthcare biotechnology

The global biologics market has expanded at a CAGR of 9.8 from 2007 to 2012, to 169b in 2012. This represents 18 of the total worldwide medicine sales in 2012. Of total biologics sales, 0.4 is contributed by biosimilars in 2012. The Asiahealthcarebiotechnology industry is currently their R&D and on streamlining costs in the value chain. Healthcare revenue increased by 7% to 10.0 million (2013: 9.4 million) and divisional operating profit increased by 15% to 3.4 million (2013: 3.0 million). The diagnostic activities continued the impressive performance reported at the half year and the aggregate number of diagnostic tests conducted increased by over 70% compared with 2013.

Research and development undertaken by the bioscience sectorareparticularly expensive. R&D tax credits are a valuable source of Government support for the sector not least because they stimulate innovation. Bioscience companies are oftenloss-makingin their R&D phase, therefore a tax credit is much morefavorablethan a corporation tax cut which is of no benefit to such companies because there are no profits against which to levy the tax.

Asia Pacific Biotech Congress 2017

15th Asia Pacific Biotechnology Congress

The conference proceedings were carried out through various Scientific-sessions and plenary lectures, of which the following Speakers were highlighted as Keynote speakers:

Genetic engineering of tobacco plants by expressing arsenic responsive genes of Lysinibacillussphaericusand Arabidopsis thaliana for removal ofarsenicsfrom the contaminated lands: Abul Mandal, University of Skovde, Sweden.

Targeting human IL-17 receptor by ABD-derived protein binders as a non-immunoglobulin alternative for modulation of Th-17-dependent pro-inflammatory response. Petr Maly, BIOCEV Research Center, Czech Republic

Go here to read the rest:
Biotechnology Conferences | Health care Conferences | Osaka ...